rss

Annals of the Rheumatic Diseases
Supplementary Material

Supplementary material related to the following articles is available online:

  • B cell depletion therapy in systemic lupus erythematosus: Long term follow up and predictors of response

    • Kristine P Ng,
    • Geraldine Cambridge,
    • Maria J Leandro,
    • Jonathan CW Edwards,
    • Michael Ehrenstein,
    • and David A Isenberg
    2007 0:ard.2006.067124v1

  • Evaluation of clinically relevant changes in patient- reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement

    • Florence Tubach,
    • Philippe Ravaud,
    • Gabriel Baron,
    • Bruno Falissard,
    • Isabelle Logeart,
    • Nicholas Bellamy,
    • Claire Bombardier,
    • David T Felson,
    • Marc C Hochberg,
    • Désirée van der Heijde,
    • and Maxime Dougados
    2004 0:ard.2004.022905v1

  • Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women

    • A M Delgado-Vega,
    • J Castiblanco,
    • L M Gómez,
    • L-M Diaz-Gallo,
    • A Rojas-Villarraga,
    • and J-M Anaya
    2010 69:462-465

  • Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings

    • L Ibba-Manneschi,
    • M Manetti,
    • A F Milia,
    • I Miniati,
    • G Benelli,
    • S Guiducci,
    • F Mecacci,
    • G Mello,
    • S Di Lollo,
    • and M Matucci-Cerinic
    2010 69:458-461

  • Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level

    • E Jones,
    • S M Churchman,
    • A English,
    • M H Buch,
    • E A Horner,
    • C H Burgoyne,
    • R Reece,
    • S Kinsey,
    • P Emery,
    • D McGonagle,
    • and F Ponchel
    2010 69:450-457

  • Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use

    • D M Urech,
    • U Feige,
    • S Ewert,
    • V Schlosser,
    • M Ottiger,
    • K Polzer,
    • G Schett,
    • and P Lichtlen
    2010 69:443-449

  • Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease

    • B Terrier,
    • M C Tamby,
    • L Camoin,
    • P Guilpain,
    • A Bérezné,
    • N Tamas,
    • C Broussard,
    • F Hotellier,
    • M Humbert,
    • G Simonneau,
    • L Guillevin,
    • and L Mouthon
    2010 69:428-433

  • Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial

    • B Fautrel,
    • M Benhamou,
    • M Breban,
    • C Roy,
    • C Lenoir,
    • G Trape,
    • A Baleydier,
    • P Ravaud,
    • and M Dougados
    2010 69:424-427

  • Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy

    • Y A de Man,
    • L E Bakker-Jonges,
    • C M Dufour-van den Goorbergh,
    • S P R Tillemans,
    • H Hooijkaas,
    • J M W Hazes,
    • and R J E M Dolhain
    2010 69:420-423

  • Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

    • J H Coombs,
    • B J Bloom,
    • F C Breedveld,
    • M P Fletcher,
    • D Gruben,
    • J M Kremer,
    • R Burgos-Vargas,
    • B Wilkinson,
    • C A F Zerbini,
    • and S H Zwillich
    2010 69:413-416

  • Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

    • R M Thurlings,
    • O Teng,
    • K Vos,
    • D M Gerlag,
    • L Aarden,
    • S O Stapel,
    • J M van Laar,
    • P P Tak,
    • and G J Wolbink
    2010 69:409-412

  • Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

    • X Mariette,
    • F Tubach,
    • H Bagheri,
    • M Bardet,
    • J M Berthelot,
    • P Gaudin,
    • D Heresbach,
    • A Martin,
    • T Schaeverbeke,
    • D Salmon,
    • M Lemann,
    • O Hermine,
    • M Raphael,
    • and P Ravaud
    2010 69:400-408

  • Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

    • F Van den Bosch,
    • B Manger,
    • P Goupille,
    • N McHugh,
    • E Rødevand,
    • P Holck,
    • R F van Vollenhoven,
    • M Leirisalo-Repo,
    • O FitzGerald,
    • M Kron,
    • M Frank,
    • S Kary,
    • and H Kupper
    2010 69:394-399

  • Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

    • A Finckh,
    • A Ciurea,
    • L Brulhart,
    • B Möller,
    • U A Walker,
    • D Courvoisier,
    • D Kyburz,
    • J Dudler,
    • C Gabay,
    • and on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid Arthritis
    2010 69:387-393

  • Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

    • R A Moore,
    • O A Moore,
    • S Derry,
    • P M Peloso,
    • A R Gammaitoni,
    • and H Wang
    2010 69:374-379

  • Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese

    • K Nishimoto,
    • Y Kochi,
    • K Ikari,
    • K Yamamoto,
    • A Suzuki,
    • K Shimane,
    • Y Nakamura,
    • K Yano,
    • N Iikuni,
    • S Tsukahara,
    • N Kamatani,
    • H Okamoto,
    • H Kaneko,
    • Y Kawaguchi,
    • M Hara,
    • Y Toyama,
    • T Horiuchi,
    • K Tao,
    • K Yasutomo,
    • D Hamada,
    • N Yasui,
    • H Inoue,
    • M Itakura,
    • H Yamanaka,
    • and S Momohara
    2010 69:368-373

  • Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden

    • A Gülfe,
    • L E Kristensen,
    • T Saxne,
    • L T H Jacobsson,
    • I F Petersson,
    • and P Geborek
    2010 69:352-357

  • Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

    • S W Syversen,
    • G L Goll,
    • D van der Heijde,
    • R Landewé,
    • B A Lie,
    • S Ødegård,
    • T Uhlig,
    • P I Gaarder,
    • and T K Kvien
    2010 69:345-351

  • Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review

    • J J Luime,
    • E M Colin,
    • J M W Hazes,
    • and E Lubberts
    2010 69:337-344

  • EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

    • M J L Peters,
    • D P M Symmons,
    • D McCarey,
    • B A C Dijkmans,
    • P Nicola,
    • T K Kvien,
    • I B McInnes,
    • H Haentzschel,
    • M A Gonzalez-Gay,
    • S Provan,
    • A Semb,
    • P Sidiropoulos,
    • G Kitas,
    • Y M Smulders,
    • M Soubrier,
    • Z Szekanecz,
    • N Sattar,
    • and M T Nurmohamed
    2010 69:325-331

  • HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus

    • A M Jacobi,
    • H Mei,
    • B F Hoyer,
    • I M Mumtaz,
    • K Thiele,
    • A Radbruch,
    • G-R Burmester,
    • F Hiepe,
    • and T Dörner
    2010 69:305-308

  • Transforming growth factor β1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis

    • K Warstat,
    • M Hoberg,
    • M Rudert,
    • S Tsui,
    • T Pap,
    • B Angres,
    • M Essl,
    • T J Smith,
    • W W Cruikshank,
    • G Klein,
    • S Gay,
    • and W K Aicher
    2010 69:270-275

  • Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis

    • H de Jong,
    • S E Berlo,
    • P Hombrink,
    • H G Otten,
    • W van Eden,
    • F P Lafeber,
    • A H M Heurkens,
    • J W J Bijlsma,
    • T T Glant,
    • and B J Prakken
    2010 69:255-262

  • Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

    • Y Allanore,
    • C Meune,
    • M C Vonk,
    • P Airo,
    • E Hachulla,
    • P Caramaschi,
    • G Riemekasten,
    • F Cozzi,
    • L Beretta,
    • C T Derk,
    • A Komócsi,
    • D Farge,
    • A Balbir,
    • V Riccieri,
    • O Distler,
    • A Chialà,
    • N Del Papa,
    • K Pasalic Simic,
    • M Ghio,
    • B Stamenkovic,
    • S Rednic,
    • N Host,
    • R Pellerito,
    • E Zegers,
    • A Kahan,
    • U A Walker,
    • M Matucci-Cerinic,
    • and EUSTAR co-authors
    2010 69:218-221

  • Role of European mitochondrial DNA haplogroups in the prevalence of hip osteoarthritis in Galicia, Northern Spain

    • I Rego,
    • M Fernández-Moreno,
    • C Fernández-López,
    • J J Gómez-Reino,
    • A González,
    • J Arenas,
    • and F J Blanco
    2010 69:210-213

  • Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis

    • A Komócsi,
    • T Pintér,
    • R Faludi,
    • B Magyari,
    • J Bozó,
    • G Kumánovics,
    • T Minier,
    • J Radics,
    • and L Czirják
    2010 69:202-205

  • The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents

    • M Boers
    2010 69:186-192

  • Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis

    • J Martin,
    • C Walsh,
    • A Gibbs,
    • T McDonnell,
    • U Fearon,
    • J Keane,
    • M B Codd,
    • J Dodd,
    • D Veale,
    • O FitzGerald,
    • and B Bresnihan
    2010 69:181-185

  • Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus

    • Y Molad,
    • M Amit-Vasina,
    • O Bloch,
    • E Yona,
    • and M J Rapoport
    2010 69:175-180

  • Does cartilage volume or thickness distinguish knees with and without mild radiographic osteoarthritis? The Framingham Study

    • S Reichenbach,
    • M Yang,
    • F Eckstein,
    • J Niu,
    • D J Hunter,
    • C E McLennan,
    • A Guermazi,
    • F Roemer,
    • M Hudelmaier,
    • P Aliabadi,
    • and D T Felson
    2010 69:143-149

  • Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis

    • F H M Prince,
    • L M Geerdink,
    • G J J M Borsboom,
    • M Twilt,
    • M A J van Rossum,
    • E P A H Hoppenreijs,
    • R ten Cate,
    • Y Koopman-Keemink,
    • M van Santen-Hoeufft,
    • H Raat,
    • and L W A van Suijlekom-Smit
    2010 69:138-142

  • Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

    • X Chevalier,
    • J Jerosch,
    • P Goupille,
    • N van Dijk,
    • F P Luyten,
    • D L Scott,
    • F Bailleul,
    • and K Pavelka
    2010 69:113-119

  • ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health

    • A Boonen,
    • J Braun,
    • I E van der Horst Bruinsma,
    • F Huang,
    • W Maksymowych,
    • N Kostanjsek,
    • A Cieza,
    • G Stucki,
    • and D van der Heijde
    2010 69:102-107

  • Measure of function in rheumatoid arthritis: individualised or classical scales?

    • R Seror,
    • F Tubach,
    • G Baron,
    • F Guillemin,
    • and P Ravaud
    2010 69:97-101

  • Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies

    • D Sugiyama,
    • K Nishimura,
    • K Tamaki,
    • G Tsuji,
    • T Nakazawa,
    • A Morinobu,
    • and S Kumagai
    2010 69:70-81

  • The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

    • F A Houssiau,
    • C Vasconcelos,
    • D D’Cruz,
    • G D Sebastiani,
    • E de Ramon Garrido,
    • M G Danieli,
    • D Abramovicz,
    • D Blockmans,
    • A Cauli,
    • H Direskeneli,
    • M Galeazzi,
    • A Gül,
    • Y Levy,
    • P Petera,
    • R Popovic,
    • R Petrovic,
    • R A Sinico,
    • R Cattaneo,
    • J Font,
    • G Depresseux,
    • J-P Cosyns,
    • and R Cervera
    2010 69:61-64

  • Gene–environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis

    • E W Karlson,
    • S-C Chang,
    • J Cui,
    • L B Chibnik,
    • P A Fraser,
    • I De Vivo,
    • and K H Costenbader
    2010 69:54-60

  • Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

    • L C Coates,
    • J Fransen,
    • and P S Helliwell
    2010 69:48-53

  • Lupus-specific health outcome measure for US patients: the LupusQoL-US version

    • M Jolly,
    • A S Pickard,
    • C Wilke,
    • R A Mikolaitis,
    • L-S Teh,
    • K McElhone,
    • L Fogg,
    • and J Block
    2010 69:29-33

  • Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

    • G Ruiz-Irastorza,
    • M Ramos-Casals,
    • P Brito-Zeron,
    • and M A Khamashta
    2010 69:20-28

  • Magnetic resonance imaging for low back pain: indications and limitations

    • N J Sheehan
    2010 69:7-11

  • Definition of arthritis candidate risk genes by combining rat linkage-mapping results with human case-control association data

    • L Bäckdahl,
    • J P Guo,
    • M Jagodic,
    • K Becanovic,
    • B Ding,
    • T Olsson,
    • and J C Lorentzen
    2009 68:1925-1932

  • FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment

    • S Raghavan,
    • D Cao,
    • M Widhe,
    • K Roth,
    • J Herrath,
    • M Engström,
    • G Roncador,
    • A H Banham,
    • C Trollmo,
    • A I Catrina,
    • and V Malmström
    2009 68:1908-1915

  • Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

    • G R Burmester,
    • P Mease,
    • B A C Dijkmans,
    • K Gordon,
    • D Lovell,
    • R Panaccione,
    • J Perez,
    • and A L Pangan
    2009 68:1863-1869

  • Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials

    • C Gaujoux-Viala,
    • M Dougados,
    • and L Gossec
    2009 68:1843-1849

  • Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

    • J N Hoes,
    • J W G Jacobs,
    • S M M Verstappen,
    • J W J Bijlsma,
    • and G J M G Van der Heijden
    2009 68:1833-1838

  • Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

    • C Mukhtyar,
    • R Lee,
    • D Brown,
    • D Carruthers,
    • B Dasgupta,
    • S Dubey,
    • O Flossmann,
    • C Hall,
    • J Hollywood,
    • D Jayne,
    • R Jones,
    • P Lanyon,
    • A Muir,
    • D Scott,
    • L Young,
    • and R A Luqmani
    2009 68:1827-1832

  • Development of quality indicators for monitoring of the disease course in rheumatoid arthritis

    • L T C van Hulst,
    • J Fransen,
    • A A den Broeder,
    • R Grol,
    • P L C M van Riel,
    • and M E J L Hulscher
    2009 68:1805-1810

  • Genetic variation in the GDF5 region is associated with osteoarthritis, height, hip axis length and fracture risk: the Rotterdam study

    • R B A Vaes,
    • F Rivadeneira,
    • J M Kerkhof,
    • A Hofman,
    • H A P Pols,
    • A G Uitterlinden,
    • and J B J van Meurs
    2009 68:1754-1760

  • STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk

    • A-K Abelson,
    • A M Delgado-Vega,
    • S V Kozyrev,
    • E Sánchez,
    • R Velázquez-Cruz,
    • N Eriksson,
    • J Wojcik,
    • M V P Linga Reddy,
    • G Lima,
    • S D’Alfonso,
    • S Migliaresi,
    • V Baca,
    • L Orozco,
    • T Witte,
    • N Ortego-Centeno,
    • the AADEA group,
    • H Abderrahim,
    • B A Pons-Estel,
    • C Gutiérrez,
    • A Suárez,
    • M F González-Escribano,
    • J Martin,
    • and M E Alarcón-Riquelme
    2009 68:1746-1753

  • Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative

    • L Gossec,
    • M Dougados,
    • N Rincheval,
    • A Balanescu,
    • D T Boumpas,
    • S Canadelo,
    • L Carmona,
    • J-P Daurès,
    • M de Wit,
    • B A C Dijkmans,
    • M Englbrecht,
    • Z Gunendi,
    • T Heiberg,
    • J R Kirwan,
    • E M Mola,
    • M Matucci-Cerinic,
    • K Otsa,
    • G Schett,
    • T Sokka,
    • G A Wells,
    • G J Aanerud,
    • A Celano,
    • A Dudkin,
    • C Hernandez,
    • K Koutsogianni,
    • F N Akca,
    • A-M Petre,
    • P Richards,
    • M Scholte-Voshaar,
    • G Von Krause,
    • and T K Kvien
    2009 68:1680-1685

  • Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database

    • T Sokka,
    • H Kautiainen,
    • T Pincus,
    • S Toloza,
    • G da Rocha Castelar Pinheiro,
    • J Lazovskis,
    • M L Hetland,
    • T Peets,
    • K Immonen,
    • J F Maillefert,
    • A A Drosos,
    • R Alten,
    • C Pohl,
    • B Rojkovich,
    • B Bresnihan,
    • P Minnock,
    • M Cazzato,
    • S Bombardieri,
    • S Rexhepi,
    • M Rexhepi,
    • D Andersone,
    • S Stropuviene,
    • M Huisman,
    • S Sierakowski,
    • D Karateev,
    • V Skakic,
    • A Naranjo,
    • E Baecklund,
    • D Henrohn,
    • F Gogus,
    • H Badsha,
    • A Mofti,
    • P Taylor,
    • C McClinton,
    • and Y Yazici
    2009 68:1666-1672

  • Musculoskeletal manifestations of lysosomal storage disorders

    • M Aldenhoven,
    • R J B Sakkers,
    • J Boelens,
    • T J de Koning,
    • and N M Wulffraat
    2009 68:1659-1665

  • Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway

    • I González-Alvaro,
    • A M Ortiz,
    • C Domínguez-Jiménez,
    • A Aragón-Bodi,
    • B Díaz Sánchez,
    • and F Sánchez-Madrid
    2009 68:1644-1650

  • Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the ubiquitin proteasome pathway

    • C Wright,
    • M Edelmann,
    • K diGleria,
    • S Kollnberger,
    • H Kramer,
    • S McGowan,
    • K McHugh,
    • S Taylor,
    • B Kessler,
    • and P Bowness
    2009 68:1626-1632

  • The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

    • R Terkeltaub,
    • J S Sundy,
    • H R Schumacher,
    • F Murphy,
    • S Bookbinder,
    • S Biedermann,
    • R Wu,
    • S Mellis,
    • and A Radin
    2009 68:1613-1617

  • Dual energy computed tomography in tophaceous gout

    • H K Choi,
    • A M Al-Arfaj,
    • A Eftekhari,
    • P L Munk,
    • K Shojania,
    • G Reid,
    • and S Nicolaou
    2009 68:1609-1612

  • Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis

    • R Torres,
    • L Macdonald,
    • S D Croll,
    • J Reinhardt,
    • A Dore,
    • S Stevens,
    • D M Hylton,
    • J S Rudge,
    • R Liu-Bryan,
    • R A Terkeltaub,
    • G D Yancopoulos,
    • and A J Murphy
    2009 68:1602-1608

  • Orthopaedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health-related quality of life

    • H Osnes-Ringen,
    • T K Kvien,
    • J E Henriksen,
    • P Mowinckel,
    • and H Dagfinrud
    2009 68:1596-1601

  • Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group

    • M Rudwaleit,
    • A G Jurik,
    • K-G A Hermann,
    • R Landewé,
    • D van der Heijde,
    • X Baraliakos,
    • H Marzo-Ortega,
    • M Østergaard,
    • J Braun,
    • and J Sieper
    2009 68:1520-1527

  • Homozygosity for DNASE2 single nucleotide polymorphisms in the 5'-regulatory region is associated with rheumatoid arthritis

    • M Rossol,
    • M Pierer,
    • S Arnold,
    • G Keyßer,
    • H Burkhardt,
    • C Baerwald,
    • and U Wagner
    2009 68:1498-1503

  • Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis

    • B Kuriya,
    • C K Cheng,
    • H M Chen,
    • and V P Bykerk
    2009 68:1482-1485

  • A descriptive and prognostic study of systemic sclerosis-associated myopathies

    • B Ranque,
    • F-J Authier,
    • V Le-Guern,
    • C Pagnoux,
    • A Berezne,
    • Y Allanore,
    • D Launay,
    • E Hachulla,
    • A Kahan,
    • J Cabane,
    • R Gherardi,
    • L Guillevin,
    • and L Mouthon
    2009 68:1474-1477

  • Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis

    • B J Radovits,
    • W Kievit,
    • J Fransen,
    • M A F J van de Laar,
    • T L Jansen,
    • P L C M van Riel,
    • and R F J M Laan
    2009 68:1470-1473

  • Prevalence of radiographic lumbar spondylosis and its association with low back pain in elderly subjects of population-based cohorts: the ROAD study

    • S Muraki,
    • H Oka,
    • T Akune,
    • A Mabuchi,
    • Y En-yo,
    • M Yoshida,
    • A Saika,
    • T Suzuki,
    • H Yoshida,
    • H Ishibashi,
    • S Yamamoto,
    • K Nakamura,
    • H Kawaguchi,
    • and N Yoshimura
    2009 68:1401-1406

  • Treatment recommendations for psoriatic arthritis

    • C T Ritchlin,
    • A Kavanaugh,
    • D D Gladman,
    • P J Mease,
    • P Helliwell,
    • W-H Boehncke,
    • K de Vlam,
    • D Fiorentino,
    • O FitzGerald,
    • A B Gottlieb,
    • N J McHugh,
    • P Nash,
    • A A Qureshi,
    • E R Soriano,
    • W J Taylor,
    • and for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    2009 68:1387-1394

  • ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version

    • U Kiltz,
    • D van der Heijde,
    • H Mielants,
    • E Feldtkeller,
    • J Braun,
    • and on behalf of the PARE/EULAR patient initiative group
    2009 68:1381-1386

  • Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15

    • C Bocelli-Tyndall,
    • L Bracci,
    • S Schaeren,
    • C Feder-Mengus,
    • A Barbero,
    • A Tyndall,
    • and G C Spagnoli
    2009 68:1352-1359

  • Regulatory IL4+CD8+ T cells in patients with ankylosing spondylitis and healthy controls

    • L Zhang,
    • L B Jarvis,
    • H-J Baek,
    • and J S Hill Gaston
    2009 68:1345-1351

  • Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis

    • C Trocmé,
    • H Marotte,
    • A Baillet,
    • B Pallot-Prades,
    • J Garin,
    • L Grange,
    • P Miossec,
    • J Tebib,
    • F Berger,
    • M J Nissen,
    • R Juvin,
    • F Morel,
    • and P Gaudin
    2009 68:1328-1333

  • Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders

    • Y Masaki,
    • L Dong,
    • N Kurose,
    • K Kitagawa,
    • Y Morikawa,
    • M Yamamoto,
    • H Takahashi,
    • Y Shinomura,
    • K Imai,
    • T Saeki,
    • A Azumi,
    • S Nakada,
    • E Sugiyama,
    • S Matsui,
    • T Origuchi,
    • S Nishiyama,
    • I Nishimori,
    • T Nojima,
    • K Yamada,
    • M Kawano,
    • Y Zen,
    • M Kaneko,
    • K Miyazaki,
    • K Tsubota,
    • K Eguchi,
    • K Tomoda,
    • T Sawaki,
    • T Kawanami,
    • M Tanaka,
    • T Fukushima,
    • S Sugai,
    • and H Umehara
    2009 68:1310-1315

  • Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

    • M H Buch,
    • D L Boyle,
    • S Rosengren,
    • B Saleem,
    • R J Reece,
    • L A Rhodes,
    • A Radjenovic,
    • A English,
    • H Tang,
    • G Vratsanos,
    • P O’Connor,
    • G S Firestein,
    • and P Emery
    2009 68:1220-1227

  • Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study

    • M Hoff,
    • T K Kvien,
    • J Kälvesten,
    • A Elden,
    • and G Haugeberg
    2009 68:1171-1176

  • Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis

    • C Carlens,
    • L Jacobsson,
    • L Brandt,
    • S Cnattingius,
    • O Stephansson,
    • and J Askling
    2009 68:1159-1164

  • Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis

    • O Flossmann,
    • B Baslund,
    • A Bruchfeld,
    • J W Cohen Tervaert,
    • C Hall,
    • P Heinzel,
    • B Hellmich,
    • R A Luqmani,
    • K Nemoto,
    • V Tesar,
    • and D R W Jayne
    2009 68:1125-1130

  • Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

    • W Katchamart,
    • J Trudeau,
    • V Phumethum,
    • and C Bombardier
    2009 68:1105-1112

  • Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

    • C Salliot,
    • and D van der Heijde
    2009 68:1100-1104

  • Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

    • K Visser,
    • and D van der Heijde
    2009 68:1094-1099

  • Severe impaired respiratory ciliary function in Wegener granulomatosis

    • S Ullrich,
    • H Gustke,
    • P Lamprecht,
    • W L Gross,
    • U Schumacher,
    • P Ambrosch,
    • and M Laudien
    2009 68:1067-1071

  • Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes

    • T Yatabe,
    • S Mochizuki,
    • M Takizawa,
    • M Chijiiwa,
    • A Okada,
    • T Kimura,
    • Y Fujita,
    • H Matsumoto,
    • Y Toyama,
    • and Y Okada
    2009 68:1051-1058

  • Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for replication in a wide range of sample collections

    • R Dieguez-Gonzalez,
    • M Calaza,
    • D Shi,
    • I Meulenbelt,
    • J Loughlin,
    • A Tsezou,
    • J Dai,
    • K N Malizos,
    • E P Slagboom,
    • M Kloppenburg,
    • K Chapman,
    • Q Jiang,
    • D Kremer,
    • J J Gomez-Reino,
    • N Nakajima,
    • S Ikegawa,
    • and A Gonzalez
    2009 68:1017-1021

  • Severe alterations in expression and localisation of {alpha}6β4 integrin in salivary gland acini from patients with Sjögren syndrome

    • J Velozo,
    • S Aguilera,
    • C Alliende,
    • P Ewert,
    • C Molina,
    • P Pérez,
    • L Leyton,
    • A Quest,
    • M Brito,
    • S González,
    • C Leyton,
    • M Hermoso,
    • R Romo,
    • and M-J González
    2009 68:991-996

  • Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy

    • G E Tzelepis,
    • G Kalliakosta,
    • A G Tzioufas,
    • P P Sfikakis,
    • C Mandros,
    • K A Boki,
    • C Roussos,
    • and H M Moutsopoulos
    2009 68:966-971

  • Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database

    • U A Walker,
    • A Tyndall,
    • L Czirják,
    • C P Denton,
    • D Farge-Bancel,
    • O Kowal-Bielecka,
    • U Müller-Ladner,
    • M Matucci-Cerinic,
    • and and the EUSTAR co-authors
    2009 68:856-862

  • Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

    • J Smolen,
    • R B Landewé,
    • P Mease,
    • J Brzezicki,
    • D Mason,
    • K Luijtens,
    • R F van Vollenhoven,
    • A Kavanaugh,
    • M Schiff,
    • G R Burmester,
    • V Strand,
    • J Vencovsky,
    • and D van der Heijde
    2009 68:797-804

  • Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

    • E C Keystone,
    • M C Genovese,
    • L Klareskog,
    • E C Hsia,
    • S T Hall,
    • P C Miranda,
    • J Pazdur,
    • S-C Bae,
    • W Palmer,
    • J Zrubek,
    • M Wiekowski,
    • S Visvanathan,
    • Z Wu,
    • and M U Rahman
    2009 68:789-796

  • EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

    • O Kowal-Bielecka,
    • R Landewé,
    • J Avouac,
    • S Chwiesko,
    • I Miniati,
    • L Czirjak,
    • P Clements,
    • C Denton,
    • D Farge,
    • K Fligelstone,
    • I Földvari,
    • D E Furst,
    • U Müller-Ladner,
    • J Seibold,
    • R M Silver,
    • K Takehara,
    • B Garay Toth,
    • A Tyndall,
    • G Valentini,
    • F van den Hoogen,
    • F Wigley,
    • F Zulian,
    • Marco Matucci-Cerinic,
    • and and the EUSTAR co-authors
    2009 68:620-628

  • A systematic review of ultrasonography in osteoarthritis

    • H I Keen,
    • R J Wakefield,
    • and P G Conaghan
    2009 68:611-619

  • Genetic variation in the nuclear factor {kappa}B pathway in relation to susceptibility to rheumatoid arthritis

    • R Dieguez-Gonzalez,
    • S Akar,
    • M Calaza,
    • E Perez-Pampin,
    • J Costas,
    • M Torres,
    • J L Vicario,
    • M L Velloso,
    • F Navarro,
    • J Narvaez,
    • B Joven,
    • G Herrero-Beaumont,
    • I Gonzalez-Alvaro,
    • B Fernandez-Gutierrez,
    • A R de la Serna,
    • L Carreño,
    • J Lopez-Longo,
    • R Caliz,
    • M D Collado-Escobar,
    • F J Blanco,
    • C Fernandez-Lopez,
    • A Balsa,
    • D Pascual-Salcedo,
    • J J Gomez-Reino,
    • and A Gonzalez
    2009 68:579-583

  • Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage

    • M Pombo-Suarez,
    • M T Castaño-Oreja,
    • M Calaza,
    • J Gomez-Reino,
    • and A Gonzalez
    2009 68:568-571

  • Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis

    • W H Bos,
    • G M Bartelds,
    • M Vis,
    • A R van der Horst,
    • G J Wolbink,
    • R J van de Stadt,
    • D van Schaardenburg,
    • B A C Dijkmans,
    • W F Lems,
    • M T Nurmohamed,
    • L Aarden,
    • and D Hamann
    2009 68:558-563

  • Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)

    • D D Gladman,
    • C T Schentag,
    • B D M Tom,
    • V Chandran,
    • J Brockbank,
    • C Rosen,
    • and V T Farewell
    2009 68:497-501

  • Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

    • M Dougados,
    • N Schmidely,
    • M Le Bars,
    • C Lafosse,
    • M Schiff,
    • J S Smolen,
    • D Aletaha,
    • P van Riel,
    • and G Wells
    2009 68:484-489

  • Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome

    • M E Wildenberg,
    • J M C Welzen-Coppens,
    • C G van Helden-Meeuwsen,
    • H Bootsma,
    • A Vissink,
    • N van Rooijen,
    • J P van de Merwe,
    • H A Drexhage,
    • and M A Versnel
    2009 68:420-426

  • A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population

    • K Shimane,
    • Y Kochi,
    • R Yamada,
    • Y Okada,
    • A Suzuki,
    • A Miyatake,
    • M Kubo,
    • Y Nakamura,
    • and K Yamamoto
    2009 68:377-383

  • Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative

    • D J Hunter,
    • J Niu,
    • Y Zhang,
    • S Totterman,
    • J Tamez,
    • C Dabrowski,
    • R Davies,
    • M-P Hellio Le Graverand,
    • M Luchi,
    • Y Tymofyeyev,
    • C R Beals,
    • and for the OAI Investigators
    2009 68:349-356

  • A review of instruments to assess illness representations in patients with rheumatic diseases

    • M Maas,
    • E Taal,
    • S van der Linden,
    • and A Boonen
    2009 68:305-309

  • Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease

    • N Dalbeth,
    • T Smith,
    • S Gray,
    • A Doyle,
    • P Antill,
    • M Lobo,
    • E Robinson,
    • A King,
    • J Cornish,
    • G Shalley,
    • A Gao,
    • and F M McQueen
    2009 68:279-282

  • Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-{alpha} blocking agents

    • E H Halvorsen,
    • E A Haavardsholm,
    • S Pollmann,
    • A Boonen,
    • D van der Heijde,
    • T K Kvien,
    • and Ø Molberg
    2009 68:249-252

  • Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case–control studies

    • H Källberg,
    • S Jacobsen,
    • C Bengtsson,
    • M Pedersen,
    • L Padyukov,
    • P Garred,
    • M Frisch,
    • E W Karlson,
    • L Klareskog,
    • and L Alfredsson
    2009 68:222-227

  • Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

    • S Visvanathan,
    • D van der Heijde,
    • A Deodhar,
    • C Wagner,
    • D G Baker,
    • J Han,
    • and J Braun
    2009 68:175-182

  • Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis

    • P C P M Verschueren,
    • R J U Lories,
    • M Daans,
    • I Théate,
    • P Durez,
    • R Westhovens,
    • and F P Luyten
    2009 68:117-123

  • Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus

    • G H Stummvoll,
    • R D Fritsch,
    • B Meyer,
    • E Hoefler,
    • M Aringer,
    • J S Smolen,
    • and G Steiner
    2009 68:110-116

  • Overnight variations in cortisol, interleukin 6, tumour necrosis factor {alpha} and other cytokines in people with rheumatoid arthritis

    • M G Perry,
    • J R Kirwan,
    • D S Jessop,
    • and L P Hunt
    2009 68:63-68

  • Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study

    • D Karaiskos,
    • C P Mavragani,
    • S Makaroni,
    • E Zinzaras,
    • M Voulgarelis,
    • A Rabavilas,
    • and H M Moutsopoulos
    2009 68:40-46

  • EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT

    • W Zhang,
    • M Doherty,
    • B F Leeb,
    • L Alekseeva,
    • N K Arden,
    • J W Bijlsma,
    • F Dincer,
    • K Dziedzic,
    • H J Hauselmann,
    • P Kaklamanis,
    • M Kloppenburg,
    • L S Lohmander,
    • E Maheu,
    • E Martin-Mola,
    • K Pavelka,
    • L Punzi,
    • S Reiter,
    • J Smolen,
    • G Verbruggen,
    • I Watt,
    • and I Zimmermann-Gorska
    2009 68:8-17

  • Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E2

    • E S Molloy,
    • M P Morgan,
    • G A Doherty,
    • B McDonnell,
    • J O’Byrne,
    • D J Fitzgerald,
    • and G M McCarthy
    2008 67:1773-1779

  • Cellular distribution of the C-type II lectin dendritic cell immunoreceptor (DCIR) and its expression in the rheumatic joint: identification of a subpopulation of DCIR+ T cells

    • C Eklöw,
    • D Makrygiannakis,
    • L Bäckdahl,
    • L Padyukov,
    • A-K Ulfgren,
    • J C Lorentzen,
    • and V Malmström
    2008 67:1742-1749

  • A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

    • M Dastmalchi,
    • C Grundtman,
    • H Alexanderson,
    • C P Mavragani,
    • H Einarsdottir,
    • S Barbasso Helmers,
    • K Elvin,
    • M K Crow,
    • I Nennesmo,
    • and I E Lundberg
    2008 67:1670-1677

  • The art of medicine in treating osteoarthritis: I will please

    • J W J Bijlsma,
    • and P M J Welsing
    2008 67:1653-1655

  • A novel TNFRSF1A splice mutation associated with increased nuclear factor {kappa}appaB (NF-{kappa}B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)

    • S M Churchman,
    • L D Church,
    • S Savic,
    • L R Coulthard,
    • B Hayward,
    • B Nedjai,
    • M D Turner,
    • R J Mathews,
    • E Baguley,
    • G A Hitman,
    • H C Gooi,
    • P M D Wood,
    • P Emery,
    • and M F McDermott
    2008 67:1589-1595

  • Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis

    • K P Liao,
    • K L Batra,
    • L Chibnik,
    • P H Schur,
    • and K H Costenbader
    2008 67:1557-1561

  • Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells

    • D Makrygiannakis,
    • M Hermansson,
    • A-K Ulfgren,
    • A P Nicholas,
    • A J W Zendman,
    • A Eklund,
    • J Grunewald,
    • C M Skold,
    • L Klareskog,
    • and A I Catrina
    2008 67:1488-1492

  • Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome

    • C Alliende,
    • Y-J Kwon,
    • M Brito,
    • C Molina,
    • S Aguilera,
    • P Pérez,
    • L Leyton,
    • A F G Quest,
    • U Mandel,
    • E Veerman,
    • M Espinosa,
    • H Clausen,
    • C Leyton,
    • R Romo,
    • and M-J González
    2008 67:1480-1487

  • The synovitis of "non-inflammatory" orthopaedic arthropathies: a quantitative histological and immunohistochemical analysis

    • F Pessler,
    • L Dai,
    • C Diaz-Torne,
    • C Gomez-Vaquero,
    • M E Paessler,
    • D-H Zheng,
    • E Einhorn,
    • U Range,
    • C Scanzello,
    • and H R Schumacher
    2008 67:1184-1187

  • CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus

    • M Mamtani,
    • B Rovin,
    • R Brey,
    • J F Camargo,
    • H Kulkarni,
    • M Herrera,
    • P Correa,
    • S Holliday,
    • J-M Anaya,
    • and S K Ahuja
    2008 67:1076-1083

  • Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis

    • M-C Kastrinaki,
    • P Sidiropoulos,
    • S Roche,
    • J Ringe,
    • S Lehmann,
    • H Kritikos,
    • V-M Vlahava,
    • B Delorme,
    • G D Eliopoulos,
    • C Jorgensen,
    • P Charbord,
    • T Häupl,
    • D T Boumpas,
    • and H A Papadaki
    2008 67:741-749

  • Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPK{alpha}

    • K Polzer,
    • A Soleiman,
    • W Baum,
    • R Axmann,
    • J Distler,
    • K Redlich,
    • A Kilian,
    • G Krönke,
    • G Schett,
    • and J Zwerina
    2008 67:602-608

  • Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity

    • E H Halvorsen,
    • S Pollmann,
    • I-M Gilboe,
    • D van der Heijde,
    • R Landewé,
    • S Ødegård,
    • T K Kvien,
    • and Ø Molberg
    2008 67:414-417

  • Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome

    • D Alpert,
    • L A Mandl,
    • D Erkan,
    • W Yin,
    • E I Peerschke,
    • and J E Salmon
    2008 67:395-401

  • The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston–Leeds Osteoarthritis Knee Score)

    • D J Hunter,
    • G H Lo,
    • D Gale,
    • A J Grainger,
    • A Guermazi,
    • and P G Conaghan
    2008 67:206-211

  • Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging

    • I H Song,
    • G R Burmester,
    • M Backhaus,
    • C E Althoff,
    • K G Hermann,
    • A K Scheel,
    • C Werner,
    • T Knetsch,
    • and M Schoenharting
    2008 67:19-25

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

    • D E Furst,
    • F C Breedveld,
    • J R Kalden,
    • J S Smolen,
    • G R Burmester,
    • J Sieper,
    • P Emery,
    • E C Keystone,
    • M H Schiff,
    • P Mease,
    • P L C M van Riel,
    • R Fleischmann,
    • M H Weisman,
    • and M E Weinblatt
    2007 66:iii2-iii22

  • Advances in targeted therapies IX 2007 66:iii1-iii95

  • EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

    • J N Hoes,
    • J W G Jacobs,
    • M Boers,
    • D Boumpas,
    • F Buttgereit,
    • N Caeyers,
    • E H Choy,
    • M Cutolo,
    • J A P Da Silva,
    • G Esselens,
    • L Guillevin,
    • I Hafstrom,
    • J R Kirwan,
    • J Rovensky,
    • A Russell,
    • K G Saag,
    • B Svensson,
    • R Westhovens,
    • H Zeidler,
    • and J W J Bijlsma
    2007 66:1560-1567

  • MRI of enthesitis of the appendicular skeleton in spondyloarthritis

    • Iris Eshed,
    • Matthias Bollow,
    • Dennis G McGonagle,
    • Ai Lyn Tan,
    • Christian E Althoff,
    • Patrick Asbach,
    • and Kay-Geert A Hermann
    2007 66:1553-1559

  • QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

    • Tuulikki Sokka,
    • Hannu Kautiainen,
    • Sergio Toloza,
    • Heidi Mäkinen,
    • Suzan M M Verstappen,
    • Merete Lund Hetland,
    • Antonio Naranjo,
    • Eva Baecklund,
    • Gertraud Herborn,
    • Rolf Rau,
    • Massimiliano Cazzato,
    • Laure Gossec,
    • Vlado Skakic,
    • Feride Gogus,
    • Stanislaw Sierakowski,
    • Barry Bresnihan,
    • Peter Taylor,
    • Catherine McClinton,
    • Theodore Pincus,
    • and for the QUEST-RA Group
    2007 66:1491-1496

  • Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment

    • Peter M ten Klooster,
    • Martine M Veehof,
    • Erik Taal,
    • Piet L C M van Riel,
    • and Mart A F J van de Laar
    2007 66:1485-1490

  • A novel gene variation of TNF{alpha} associated with ankylosing spondylitis: a reconfirmed study

    • Xiaoquan Zhu,
    • Yawen Wang,
    • Liang Sun,
    • Yuguo Song,
    • Fei Sun,
    • Lei Tang,
    • Zhenghao Huo,
    • Jianxin Li,
    • and Ze Yang
    2007 66:1419-1422

  • Investigation of association between the TRAF family genes and RA susceptibility

    • Catherine Potter,
    • Stephen Eyre,
    • Andrew Cope,
    • Jane Worthington,
    • and Anne Barton
    2007 66:1322-1326

  • Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

    • Mahboob U Rahman,
    • Ingrid Strusberg,
    • Piet Geusens,
    • Alberto Berman,
    • David Yocum,
    • Daniel Baker,
    • Carrie Wagner,
    • John Han,
    • and Rene Westhovens
    2007 66:1233-1238

  • CORRECTION 2007 66:1128

  • Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis

    • Emma P K Yu,
    • Andrew J K Ostor,
    • and Frances C Hall
    2007 66:1122-1123

  • Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients

    • T C T M van der Pouw Kraan,
    • C A Wijbrandts,
    • L G M van Baarsen,
    • A E Voskuyl,
    • F Rustenburg,
    • J M Baggen,
    • S M Ibrahim,
    • M Fero,
    • B A C Dijkmans,
    • P P Tak,
    • and C L Verweij
    2007 66:1008-1014

  • Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK

    • Hector Chinoy,
    • Fiona Salway,
    • Sally John,
    • Noreen Fertig,
    • Brian D Tait,
    • Chester V Oddis,
    • William E R Ollier,
    • Robert G Cooper,
    • and The UK Adult Onset Myositis Immunogenetic Collaboration
    2007 66:970-973

  • Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population

    • Kayoko Tao,
    • Mutsuko Fujii,
    • Shin-ichi Tsukumo,
    • Yoichi Maekawa,
    • Kenji Kishihara,
    • Yasutaka Kimoto,
    • Takahiko Horiuchi,
    • Hajime Hisaeda,
    • Shizuo Akira,
    • Shoji Kagami,
    • and Koji Yasutomo
    2007 66:905-909

  • Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus

    • Peter E Westerweel,
    • Remco K M A C Luijten,
    • Imo E Hoefer,
    • Hein A Koomans,
    • Ronald H W M Derksen,
    • and Marianne C Verhaar
    2007 66:865-870

  • Reversal of Sjögren’s-like syndrome in non-obese diabetic mice

    • Simon D Tran,
    • Shohta Kodama,
    • Beatrijs M Lodde,
    • Ildiko Szalayova,
    • Sharon Key,
    • Saeed Khalili,
    • Denise L Faustman,
    • and Éva Mezey
    2007 66:812-814

  • Ectopic lymphoid neogenesis in psoriatic arthritis

    • Juan D Cañete,
    • Begoña Santiago,
    • Tineke Cantaert,
    • Raimon Sanmartí,
    • Antonio Palacin,
    • Raquel Celis,
    • Eduard Graell,
    • Beatriz Gil-Torregrosa,
    • Dominique Baeten,
    • and José L Pablos
    2007 66:720-726

  • Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines

    • Wolfgang Hueber,
    • Beren H Tomooka,
    • Xiaoyan Zhao,
    • Brian A Kidd,
    • Jan W Drijfhout,
    • James F Fries,
    • Walther J van Venrooij,
    • Allan L Metzger,
    • Mark C Genovese,
    • and William H Robinson
    2007 66:712-719

  • The public neglect of rheumatic diseases: insights from analyses of attendees in a musculoskeletal disease awareness activity

    • Klaus P Machold,
    • Marcus D Köller,
    • Stephan Pflugbeil,
    • Christof Zimmermann,
    • Ernst Wagner,
    • Ulrike Stuby,
    • Daniel Aletaha,
    • Tanja A Stamm,
    • Franz Mayrhofer,
    • Attila Dunky,
    • Josef Hermann,
    • Wilfried Ilias,
    • Josef S Smolen,
    • and the Rheuma-Bus group of physicians
    2007 66:697-699

  • Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils

    • Rachel Colman,
    • Abdullah Hussain,
    • Margaret Goodall,
    • Steven P Young,
    • Tanya Pankhurst,
    • Xiaomei Lu,
    • Royston Jefferis,
    • Caroline O S Savage,
    • and Julie M Williams
    2007 66:676-682

  • Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study

    • Wilco de Jager,
    • Esther P A H Hoppenreijs,
    • Nico M Wulffraat,
    • Lucy R Wedderburn,
    • Wietse Kuis,
    • and Berent J Prakken
    2007 66:589-598

  • Attachment to laminin-111 facilitates transforming growth factor ß-induced expression of matrix metalloproteinase-3 in synovial fibroblasts

    • Maik Hoberg,
    • Maximilian Rudert,
    • Thomas Pap,
    • Gerd Klein,
    • Steffen Gay,
    • and Wilhelm K Aicher
    2007 66:446-451

  • Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values

    • Eisuke Inoue,
    • Hisashi Yamanaka,
    • Masako Hara,
    • Taisuke Tomatsu,
    • and Naoyuki Kamatani
    2007 66:407-409

  • EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    • W Zhang,
    • M Doherty,
    • B F Leeb,
    • L Alekseeva,
    • N K Arden,
    • J W Bijlsma,
    • F Dinçer,
    • K Dziedzic,
    • H J Häuselmann,
    • G Herrero-Beaumont,
    • P Kaklamanis,
    • S Lohmander,
    • E Maheu,
    • E Martín-Mola,
    • K Pavelka,
    • L Punzi,
    • S Reiter,
    • J Sautner,
    • J Smolen,
    • G Verbruggen,
    • and I Zimmermann-Górska
    2007 66:377-388

  • Oestrogens inhibit interleukin 1ß-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-{kappa}B impairment

    • Pascal Richette,
    • Marie-France Dumontier,
    • Khadija Tahiri,
    • Magdalena Widerak,
    • Antoine Torre,
    • Mourad Benallaloua,
    • François Rannou,
    • Marie-Therese Corvol,
    • and Jean-François Savouret
    2007 66:345-350

  • Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study

    • Hilary A Capell,
    • Rajan Madhok,
    • Duncan R Porter,
    • Robin A L Munro,
    • Iain B McInnes,
    • John A Hunter,
    • Malcolm Steven,
    • Asad Zoma,
    • Elaine Morrison,
    • Martin Sambrook,
    • Fat Wui Poon,
    • Rosemary Hampson,
    • Fiona McDonald,
    • Ann Tierney,
    • Neil Henderson,
    • and Ian Ford
    2007 66:235-241

  • A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip

    • F P Luyten,
    • P Geusens,
    • M Malaise,
    • L De Clerck,
    • R Westhovens,
    • F Raeman,
    • D Vander Mijnsbrugge,
    • L Mathy,
    • J P Hauzeur,
    • F De Keyser,
    • and F Van den Bosch
    2007 66:99-106

  • Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic

    • L Heuft-Dorenbosch,
    • R Landewé,
    • R Weijers,
    • H Houben,
    • S van der Linden,
    • P Jacobs,
    • and D van der Heijde
    2007 66:92-98

  • A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients

    • L Federici,
    • C Rittore-Domingo,
    • I Koné-Paut,
    • C Jorgensen,
    • M Rodière,
    • A Le Quellec,
    • and I Touitou
    2006 65:1427-1432

  • Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions

    • C P Denton,
    • M Humbert,
    • L Rubin,
    • and C M Black
    2006 65:1336-1340

  • EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

    • W Zhang,
    • M Doherty,
    • E Pascual,
    • T Bardin,
    • V Barskova,
    • P Conaghan,
    • J Gerster,
    • J Jacobs,
    • B Leeb,
    • F Lioté,
    • G McCarthy,
    • P Netter,
    • G Nuki,
    • F Perez-Ruiz,
    • A Pignone,
    • J Pimentão,
    • L Punzi,
    • E Roddy,
    • T Uhlig,
    • and I Zimmermann-Gòrska
    2006 65:1301-1311

  • The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

    • A Kavanaugh,
    • C E Antoni,
    • D Gladman,
    • S Wassenberg,
    • B Zhou,
    • A Beutler,
    • G Keenan,
    • G Burmester,
    • D E Furst,
    • M H Weisman,
    • J R Kalden,
    • J Smolen,
    • D van der Heijde,
    • and the IMPACT Study Group
    2006 65:1038-1043

  • Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

    • M H Schiff,
    • G R Burmester,
    • J D Kent,
    • A L Pangan,
    • H Kupper,
    • S B Fitzpatrick,
    • and C Donovan
    2006 65:889-894

  • B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions

    • J Voswinkel,
    • A Mueller,
    • J A Kraemer,
    • P Lamprecht,
    • K Herlyn,
    • K Holl-Ulrich,
    • A C Feller,
    • S Pitann,
    • A Gause,
    • and W L Gross
    2006 65:859-864

  • Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

    • M E Weinblatt,
    • E C Keystone,
    • D E Furst,
    • A F Kavanaugh,
    • E K Chartash,
    • and O G Segurado
    2006 65:753-759

  • Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients

    • M Cutolo,
    • S Capellino,
    • P Montagna,
    • A Sulli,
    • B Seriolo,
    • and B Villaggio
    2006 65:728-735

  • Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery

    • A Boonen,
    • G A Matricali,
    • J Verduyckt,
    • V Taelman,
    • P Verschueren,
    • A Sileghem,
    • L Corluy,
    • and R Westhovens
    2006 65:694-695

  • Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

    • J-Y Reginster,
    • S Adami,
    • P Lakatos,
    • M Greenwald,
    • J J Stepan,
    • S L Silverman,
    • C Christiansen,
    • L Rowell,
    • N Mairon,
    • B Bonvoisin,
    • M K Drezner,
    • R Emkey,
    • D Felsenberg,
    • C Cooper,
    • P D Delmas,
    • and P D Miller
    2006 65:654-661

  • Double echo steady state magnetic resonance imaging of knee articular cartilage at 3 Tesla: a pilot study for the Osteoarthritis Initiative

    • F Eckstein,
    • M Hudelmaier,
    • W Wirth,
    • B Kiefer,
    • R Jackson,
    • J Yu,
    • C B Eaton,
    • and E Schneider
    2006 65:433-441

  • Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data

    • J A P Da Silva,
    • J W G Jacobs,
    • J R Kirwan,
    • M Boers,
    • K G Saag,
    • L B S Inês,
    • E J P de Koning,
    • F Buttgereit,
    • M Cutolo,
    • H Capell,
    • R Rau,
    • and J W J Bijlsma
    2006 65:285-293

  • Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren’s syndrome

    • B M Lodde,
    • F Mineshiba,
    • J Wang,
    • A P Cotrim,
    • S Afione,
    • P P Tak,
    • and B J Baum
    2006 65:195-200

  • Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

    • D E Furst,
    • F C Breedveld,
    • J R Kalden,
    • J S Smolen,
    • G R Burmester,
    • J W J Bijlsma,
    • M Dougados,
    • P Emery,
    • E C Keystone,
    • L Klareskog,
    • and P J Mease
    2005 64:iv2-iv14

  • Discussion: Assessment of psoriatic arthritis

    • P J Mease,
    • F Behrens,
    • W-H Boehncke,
    • S R Feldman,
    • O FitzGerald,
    • D D Gladman,
    • P S Helliwell,
    • P Nash,
    • I Olivieri,
    • W J Taylor,
    • and P-P Tak
    2005 64:ii69-ii73

  • Vasculitis, antiphospholipid antibodies, and renal artery stenosis

    • S N Paul,
    • S R Sangle,
    • A N Bennett,
    • M El-Hachmi,
    • R Hangartner,
    • G R Hughes,
    • and D P D’Cruz
    2005 64:1800-1802

  • Altered influenza virus haemagglutinin peptides inhibit T cell responses to type II collagen in rheumatoid arthritis

    • L Xia,
    • L Ru,
    • and L Zhanguo
    2005 64:1790-1791

  • Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity

    • G Zandman-Goddard,
    • M Blank,
    • P Langevitz,
    • L Slutsky,
    • M Pras,
    • Y Levy,
    • O Shovman,
    • T Witte,
    • A Doria,
    • J Rovensky,
    • and Y Shoenfeld
    2005 64:1698-1702

  • Superficial collections of fluid tophaceous material as clinical presentation of anorexia nervosa

    • C Garcia-Porrua,
    • C Canedo,
    • R Argueso,
    • and M A Gonzalez-Gay
    2005 64:1658-1659

  • Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement

    • A Boonen,
    • J L Severens,
    • A van Tubergen,
    • R Landewé,
    • G Bonsel,
    • D van der Heijde,
    • and Sj van der Linden
    2005 64:1650-1652

  • Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study

    • M Haupt,
    • S Millen,
    • M Jänner,
    • D Falagan,
    • R Fischer-Betz,
    • and M Schneider
    2005 64:1618-1623

  • Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study

    • C Bengtsson,
    • B Nordmark,
    • L Klareskog,
    • I Lundberg,
    • L Alfredsson,
    • and the EIRA study group
    2005 64:1588-1594

  • Does increasing the grades of the knee osteoarthritis line drawing atlas alter its clinimetric properties?

    • C E Wilkinson,
    • A J Carr,
    • and M Doherty
    2005 64:1467-1473

  • Topical tacrolimus treatment in a patient with dermatomyositis

    • C E Lampropoulos,
    • and D P D’ Cruz
    2005 64:1376-1377

  • Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis

    • E Krishnan,
    • A Häkkinen,
    • T Sokka,
    • and P Hannonen
    2005 64:1350-1352

  • Course and prognosis of elbow complaints: a cohort study in general practice

    • S D M Bot,
    • J M van der Waal,
    • C B Terwee,
    • D A W M van der Windt,
    • L M Bouter,
    • and J Dekker
    2005 64:1331-1336

  • Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

    • M Rudwaleit,
    • X Baraliakos,
    • J Listing,
    • J Brandt,
    • J Sieper,
    • and J Braun
    2005 64:1305-1310

  • Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

    • C Antoni,
    • G G Krueger,
    • K de Vlam,
    • C Birbara,
    • A Beutler,
    • C Guzzo,
    • B Zhou,
    • L T Dooley,
    • A Kavanaugh,
    • and for the IMPACT 2 investigators
    2005 64:1150-1157

  • ß2 Adrenoceptor gene single nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden

    • B-Y Xu,
    • L Ärlehag,
    • S-B Rantapää-Dahlquist,
    • and A K Lefvert
    2005 64:773-776

  • EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    • W Zhang,
    • M Doherty,
    • N Arden,
    • B Bannwarth,
    • J Bijlsma,
    • K-P Gunther,
    • H J Hauselmann,
    • G Herrero-Beaumont,
    • K Jordan,
    • P Kaklamanis,
    • B Leeb,
    • M Lequesne,
    • S Lohmander,
    • B Mazieres,
    • E Martin-Mola,
    • K Pavelka,
    • A Pendleton,
    • L Punzi,
    • B Swoboda,
    • R Varatojo,
    • G Verbruggen,
    • I Zimmermann-Gorska,
    • and M Dougados
    2005 64:669-681

  • Who cares about team care? Conference report from CARE II. Spenshult, Sweden, 18–20 September 2003

    • I F Petersson,
    • A Bremander,
    • L Klareskog,
    • and C H Stenström
    2005 64:644

  • Summary of report of the 3rd Workshop of European Biologics Registries

    • A Zink,
    • A Silman,
    • and L Klareskog
    2005 64:644

  • Standardised work-up programme for fever of unknown origin and contribution of magnetic resonance imaging for the diagnosis of hidden systemic vasculitis

    • A D Wagner,
    • J Andresen,
    • E Raum,
    • J Lotz,
    • H Zeidler,
    • J G Kuipers,
    • and M C Jendro
    2005 64:105-110

  • Prevalence and determinants of one month hand pain and hand related disability in the elderly (Rotterdam study)

    • S Dahaghin,
    • S M A Bierma-Zeinstra,
    • M Reijman,
    • H A P Pols,
    • J M W Hazes,
    • and B W Koes
    2005 64:99-104

  • Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state

    • F Tubach,
    • P Ravaud,
    • G Baron,
    • B Falissard,
    • I Logeart,
    • N Bellamy,
    • C Bombardier,
    • D Felson,
    • M Hochberg,
    • D van der Heijde,
    • and M Dougados
    2005 64:34-37

  • Interrater reproducibility of clinical tests for rotator cuff lesions

    • A J K Ostor,
    • C A Richards,
    • A T Prevost,
    • B L Hazleman,
    • and C A Speed
    2004 63:1288-1292

  • Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis?

    • A Boonen,
    • D van der Heijde,
    • R Landewé,
    • A Chorus,
    • W van Lankveld,
    • H Miedema,
    • H van der Tempel,
    • and S van der Linden
    2004 63:1264-1268

  • CORRECTION 2004 63:1182

  • Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies

    • G Espinosa,
    • S Bucciarelli,
    • R Cervera,
    • M Lozano,
    • J-C Reverter,
    • G de la Red,
    • V Gil,
    • M Ingelmo,
    • J Font,
    • and R A Asherson
    2004 63:730-736

  • Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis

    • J P Morko,
    • M Söderström,
    • A-M K Säämänen,
    • H J Salminen,
    • and E I Vuorio
    2004 63:649-655

  • Influence of hip dysplasia on the development of osteoarthritis of the hip

    • A M Lievense,
    • S M A Bierma-Zeinstra,
    • A P Verhagen,
    • J A N Verhaar,
    • and B W Koes
    2004 63:621-626

  • Clinimetric evaluation of shoulder disability questionnaires: a systematic review of the literature

    • S D M Bot,
    • C B Terwee,
    • D A W M van der Windt,
    • L M Bouter,
    • J Dekker,
    • and H C W de Vet
    2004 63:335-341

  • Tenascin and aggrecan expression by articular chondrocytes is influenced by interleukin 1ß: a possible explanation for the changes in matrix synthesis during osteoarthritis

    • D Pfander,
    • N Heinz,
    • P Rothe,
    • H-D Carl,
    • and B Swoboda
    2004 63:240-244

  • Validity, reliability, and applicability of seven definitions of hip osteoarthritis used in epidemiological studies: a systematic appraisal

    • M Reijman,
    • J M W Hazes,
    • B W Koes,
    • A P Verhagen,
    • and S M A Bierma-Zeinstra
    2004 63:226-232

  • Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts

    • M George,
    • B Stein,
    • O Müller,
    • M Weis-Klemm,
    • T Pap,
    • W J Parak,
    • and W K Aicher
    2004 63:67-70

  • Costs of ankylosing spondylitis in three European countries: the patient’s perspective

    • A Boonen,
    • D van der Heijde,
    • R Landewé,
    • F Guillemin,
    • A Spoorenberg,
    • H Schouten,
    • M Rutten-van Mölken,
    • M Dougados,
    • H Mielants,
    • K de Vlam,
    • H van der Tempel,
    • and Sj van der Linden
    2003 62:741-747

  • Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries

    • A Boonen,
    • D van der Heijde,
    • R Landewé,
    • F Guillemin,
    • M Rutten-van Mölken,
    • M Dougados,
    • H Mielants,
    • K de Vlam,
    • H van der Tempel,
    • S Boesen,
    • A Spoorenberg,
    • H Schouten,
    • and Sj van der Linden
    2003 62:732-740

  • Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial

    • A H Gerards,
    • R B M Landewé,
    • A P A Prins,
    • G A W Bruijn,
    • H S Goei Thé,
    • R F J M Laan,
    • and B A C Dijkmans
    2003 62:291-296

  • International variation in hip replacement rates

    • H Merx,
    • K Dreinhöfer,
    • P Schräder,
    • T Stürmer,
    • W Puhl,
    • K-P Günther,
    • and H Brenner
    2003 62:222-226

  • Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa

    • A D Filer,
    • J M Gardner-Medwin,
    • J Thambyrajah,
    • K Raza,
    • D M Carruthers,
    • R J Stevens,
    • L Liu,
    • S E Lowe,
    • J N Townend,
    • and P A Bacon
    2003 62:162-167

  • Adrenomedullin in synovial fluids from patients with rheumatoid arthritis inhibits interleukin 6 production from synoviocytes

    • Y Nanke,
    • S Kotake,
    • K Yonemoto,
    • S Saito,
    • T Tomatsu,
    • and N Kamatani
    2003 62:82-83

  • Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

    • L C Doward,
    • A Spoorenberg,
    • S A Cook,
    • D Whalley,
    • P S Helliwell,
    • L J Kay,
    • S P McKenna,
    • A Tennant,
    • D van der Heijde,
    • and M A Chamberlain
    2003 62:20-26

  • Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis

    • V Strand,
    • R Landéwé,
    • and D van der Heijde
    2002 61:ii64-ii66

  • Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis

    • M J López-Armada,
    • O Sánchez-Pernaute,
    • R Largo,
    • I Diez-Ortego,
    • I Palacios,
    • J Egido,
    • and G Herrero-Beaumont
    2002 61:1027-1030

  • Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints

    • M Backhaus,
    • G R Burmester,
    • D Sandrock,
    • D Loreck,
    • D Hess,
    • A Scholz,
    • S Blind,
    • B Hamm,
    • and M Bollow
    2002 61:895-904

  • Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinaemia with pulse cyclophosphamide

    • J Thiel,
    • T Peters,
    • A Mas Marques,
    • B Rösler,
    • H H Peter,
    • and S M Weiner
    2002 61:838-841

  • Magnetic resonance imaging in the diagnosis and follow up of Takayasu's arteritis in children

    • V P R Aluquin,
    • S A Albano,
    • F Chan,
    • C Sandborg,
    • and P T Pitlick
    2002 61:526-529

  • Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis

    • G Schett,
    • S Winkler,
    • U Hollenstein,
    • G Amann,
    • M Willheim,
    • M Prokop,
    • W Klepetko,
    • A Becherer,
    • J Smolen,
    • and W Graninger
    2002 61:463-467

  • Heavy cigarette smoking and RA

    • A T MASI,
    • J C ALDAG,
    • R L MALAMET,
    • D HUTCHINSON,
    • and R MOOTS
    2001 60:1154-1155

  • Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis

    • Å Reckner Olsson,
    • T Skogh,
    • and G Wingren
    2001 60:934-939

  • Quantitative ultrasonography in rheumatoid arthritis: evaluation of inflammation by Doppler technique

    • E Qvistgaard,
    • H Røgind,
    • S Torp-Pedersen,
    • L Terslev,
    • B Danneskiold-Samsøe,
    • and H Bliddal
    2001 60:690-693

  • Advances in targeted therapies II

    • GUEST EDITORS,
    • F C BREEDVELD,
    • J R KALDEN,
    • and J S SMOLEN
    2000 59:i

  • Correction for vol. 59, p. 394 2000 59:656

Register for free content


Free trial
Individuals may register for a free 60 day online trial to all content.

Free archive
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.